DRG Epidemiology's coverage of multiple myeloma comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the incidence and prevalence of multiple myeloma for each country, as well as annualized case counts projected to the national population.

Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets and 10 years for the other countries covered in this report. In addition to forecasting incident and prevalent patient populations, the number of drug-treatment opportunities at specific lines of therapy are also forecast across the developed world.

DRG Epidemiology's multiple myeloma forecast will answer the following questions:

  • In developing countries, what impact will economic growth and development have on the number of people diagnosed with multiple myeloma per year?
  • Of all people diagnosed with multiple myeloma, how many in each country across the developed world are drug-treated?
  • How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of multiple myeloma over the forecast period?

All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods. In addition, we provide a graphical depiction of the patient flow between or within different disease states for the major mature pharmaceutical markets. These patient flow diagrams are provided at the regional level but may be requested for any specific country or forecast year.

DRG Epidemiology provides at least ten years of forecast data for the following multiple myeloma patient populations:

  • Multiple Myeloma DDiagnosed iIncident cCases. - Multiple Myeloma
  • Diagnosed iIncident cCases by sStage dDistribution. - Multiple Myeloma
  • Diagnosed iIncident cCases by symptomatic status.- Multiple Myeloma
  • Multiple Myeloma Diagnosed first-l Line dDrug-tTreatable pPopulation.
  • First-l1st Line drug-treatable population DTP by tTransplant e-Eligibility sStatus.
  • First-l1st Line tTransplant-eEligible dDrug-tTreatment subpopulation(s).
  • First-l1st Line tTransplant-iIneligible dDrug-tTreatment subpopulation(s).
  • 2nd LSecond-line drug-treatable population DTP dDrug-tTreatment subpopulation(s).
  • Multiple Myeloma Diagnosed second-l2nd Line dDrug-tTreatable pPopulation.
  • Multiple Myeloma Diagnosed MGUS iIncident cCases.- MGUS
  • Multiple Myeloma Total MGUS pPrevalent cCases.- MGUS

… and more (details available on request).

Note: Ccoverage may vary by country and region.

Table of contents

  • Multiple Myeloma - Epidemiology - Mature Markets
    • Introduction
      • Overview
        • Diagnosed Incidence of Multiple Myeloma per 100,000 Among People of All Ages in 2020 and 2040
        • Patient Flow: Multiple Myeloma
        • Relative Sizes of the Factors Contributing to the Trend in Incident Cases of Multiple Myeloma Over the Next 20 Years
        • Analysis of the Diagnosed Incident Cases of Multiple Myeloma in 2020 by ISS Stage
        • Analysis of the Diagnosed Incident Cases of Multiple Myeloma in 2020 by Symptoms
    • Epidemiology Data
    • Methods
      • Diagnosed Incident Cases of Multiple Myeloma
      • ISS Stage Distribution
      • Diagnosed Incident Cases of Multiple Myeloma by Symptoms
      • Asymptomatic Cases by Risk Stratification
      • Asymptomatic Multiple Myeloma Progression to Symptomatic Multiple Myeloma
      • Diagnosed Prevalent Cases of Multiple Myeloma
      • Diagnosed Incident Cases of MGUS
      • MGUS Prevalent Cases
      • MGUS Progression to Multiple Myeloma
      • Lifetime DALYs Gained
      • Drug-Treatable Population and Percentage Drug-Treated
    • Reference Materials
      • Literature Review
        • Studies Included in the Analysis of Multiple Myeloma
        • Studies Excluded from the Analysis of Multiple Myeloma
      • Risk/Protective Factors
        • Risk/Protective Factors for Multiple Myeloma
      • Bibliography
      • Glossary

Author(s): Ullas Ulahannan; Nishant Kumar, M.P.H.

Ullas Ulahannan, M.P.H., is an associate epidemiologist at DRG, part of Clarivate. Prior to joining DRG, he worked at Jhpiego (a John Hopkins University affiliate) as a senior program officer evaluating, implementing, and monitoring various health programs in collaboration with the state and central governments of India. He earned a B.S. in nursing from Rajiv Gandhi University and an M.P.H. from Manipal University.

Nishant Kumar, M.P.H., is an associate director on the Epidemiology team at DRG, part of Clarivate. His areas of expertise are oncology and CNS diseases, including Alzheimer’s disease and dementia. His key interests in oncology are modeling disease progression and drug-treatable incident and prevalent populations. Prior to joining DRG, Mr. Kumar sized patient populations for rare and niche diseases, such as graft-versus-host disease and Duchenne muscular dystrophy. He earned his M.P.H. with a concentration in epidemiology and statistics from King’s College in London and a B.Sc. (Honors) in medical studies from the University of Birmingham.


Related Reports

Multiple Myeloma - Landscape & Forecast - Disease Landscape & Forecast

The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of mu...

View Details

Multiple Myeloma - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of multiple myeloma comprises epidemiological estimates of key patient populations in...

View Details

Multiple Myeloma - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key multiple myeloma patient pop...

View Details

Multiple Myeloma | Disease Landscape and Forecast | G7 | 2020

The availability of premium-priced branded agents prescribed in doublet, triplet, and quadruplet regimens, particularly Darzalex-based therapies, has had an impressive impact on the treatment of mu...

View Details